Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 681 - 690 of 1165

Blood glucose test strips (blood glucose test strips)

Status:

Concluded without agreement

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Blood glucose test strips (blood glucose test strips)

Status:

Concluded without agreement

Manufacturer:

Nova Biomedical Canada Ltd.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Blood glucose test strips (blood glucose test strips)

Status:

Concluded without agreement

Manufacturer:

Auto Control Medical Inc

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

MediSure Canada Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

LifeScan Canada ULC

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

I-Sens, Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

BTNX Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

Ascensia Diabetes Care

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

Spirit Healthcare Group

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Blood glucose test strips (blood glucose test strips)

Status:

Concluded with an LOI

Manufacturer:

Abbott Diabetes Care

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated December 9, 2020

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 67
  • Page 68
  • Current page 69
  • Page 70
  • Page 71
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use